Sandoz advances its biosimilars program with EMA acceptance of regulatory submission
Sandoz announced the EMA has accepted their Marketing Authorization Application for its biosimilar to Amgen's EU-licensed Neulasta®* (pegfilgrastim) - a long-acting recombinant human G-CSF. Sandoz is seeking approval for the same indication as the reference product. February 11, 2016